First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).

W. R. Schelman; S. K. Sandhu; V. Moreno Garcia; G. Wilding; L. Sun; C. Toniatti; M. Stroh; N. Kreischer; C. L. Carpenter; L. R. Molife; S. B. Kaye; J. S. De Bono; R. M. Wenham

doi:10.1200/jco.2011.29.15_suppl.3102

First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.3102 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3102-3102 ◽

Cited By ~ 11

Author(s):

W. R. Schelman ◽

S. K. Sandhu ◽

V. Moreno Garcia ◽

G. Wilding ◽

L. Sun ◽

...

Keyword(s):

Antitumor Activity ◽

Cancer Patients ◽

Advanced Cancer ◽

Parp Inhibitor ◽

Advanced Cancer Patients ◽

Human Trial ◽

Ovarian Cancers

Get full-text (via PubEx)

First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3001 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3001-3001 ◽

Cited By ~ 19

Author(s):

S. K. Sandhu ◽

R. M. Wenham ◽

G. Wilding ◽

M. McFadden ◽

L. Sun ◽

...

Keyword(s):

Antitumor Activity ◽

Cancer Patients ◽

Advanced Cancer ◽

Parp Inhibitor ◽

Advanced Cancer Patients ◽

Human Trial ◽

Ovarian Cancers

Get full-text (via PubEx)

362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)72069-3 ◽

2010 ◽

Vol 8 (7) ◽

pp. 114-115

Author(s):

R.M. Wenham ◽

S.K. Sandhu ◽

G. Wilding ◽

L. Sun ◽

C. Toniatti ◽

...

Keyword(s):

Antitumor Activity ◽

Cancer Patients ◽

Advanced Cancer ◽

Parp Inhibitor ◽

Advanced Cancer Patients ◽

Human Trial ◽

Ovarian Cancers

Get full-text (via PubEx)

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients

JCI Insight ◽

10.1172/jci.insight.90380 ◽

2017 ◽

Vol 2 (8) ◽

Cited By ~ 11

Author(s):

Vivek Subbiah ◽

Muhammad Rizwan Khawaja ◽

David S. Hong ◽

Behrang Amini ◽

Jiang Yungfang ◽

...

Keyword(s):

Cancer Patients ◽

Advanced Cancer ◽

Advanced Cancer Patients ◽

Human Trial ◽

Vegf Inhibitor ◽

Egfr Antibody

Get full-text (via PubEx)

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy

Lung Cancer ◽

10.1016/j.lungcan.2015.06.014 ◽

2015 ◽

Vol 89 (3) ◽

pp. 306-310 ◽

Cited By ~ 10

Author(s):

M. Kossai ◽

B. Duchemann ◽

C. Boutros ◽

C. Caramella ◽

A. Hollebecque ◽

...

Keyword(s):

Antitumor Activity ◽

Drug Development ◽

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trials ◽

Development Programs ◽

Advanced Cancer Patients ◽

Clinical Drug Development ◽

Clinical Drug

Get full-text (via PubEx)

First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3009 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3009-3009 ◽

Cited By ~ 11

Author(s):

T. A. Yap ◽

A. Patnaik ◽

I. Fearen ◽

D. Olmos ◽

K. Papadopoulos ◽

...

Keyword(s):

Antitumor Activity ◽

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trial ◽

Advanced Cancer Patients ◽

Akt Inhibitor

Get full-text (via PubEx)

Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps2617 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS2617-TPS2617 ◽

Cited By ~ 5

Author(s):

Sarina Anne Piha-Paul ◽

Jennifer Brooke Goldstein ◽

Kenneth R. Hess ◽

Siqing Fu ◽

David S. Hong ◽

...

Keyword(s):

Ovarian Cancer ◽

Homologous Recombination ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Advanced Cancer Patients ◽

Pten Loss ◽

Somatic Alterations

Get full-text (via PubEx)

Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations inBRCA1/2, mutations/deletions inPTENor PTEN loss, aberrations in otherBRCApathway genes, and germline mutations inBRCA1/2(not breast or ovarian cancer)

10.1158/1535-7163.targ-17-a096 ◽

2018 ◽

Author(s):

Sarina A. Piha-Paul ◽

Wendy Wen Xiong ◽

Tyler Moss ◽

Rosa M. Mostorino ◽

Shelby Sedelmeier ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Germline Mutations ◽

Advanced Cancer Patients ◽

Pten Loss ◽

Somatic Alterations

Get full-text (via PubEx)

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

10.1158/1535-7163.targ-15-pr14 ◽

2015 ◽

Cited By ~ 5

Author(s):

Timothy A. Yap ◽

Maria J. de Miguel Luken ◽

Brent O'Carrigan ◽

Desam Roda ◽

Dionysis Papadatos-Pastos ◽

...

Keyword(s):

Antitumor Activity ◽

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Ataxia Telangiectasia ◽

Phase I Trial ◽

Preliminary Evidence ◽

Ataxia Telangiectasia Mutated ◽

Advanced Cancer Patients

Get full-text (via PubEx)

Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients

10.1158/1538-7445.am2015-ct323 ◽

2015 ◽

Cited By ~ 8

Author(s):

Vasiliki Michalarea ◽

David Lorente ◽

Juanita Lopez ◽

Suzanne Carreira ◽

Hasina Hassam ◽

...

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Dose Escalation ◽

Phase I Trial ◽

Parp Inhibitor ◽

Advanced Cancer Patients ◽

Akt Inhibitor

Get full-text (via PubEx)

Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations

10.1158/1538-7445.am2016-ct010 ◽

2016 ◽

Cited By ~ 4

Author(s):

Vasiliki Michalarea ◽

Desam Roda ◽

Yvette Drew ◽

Suzanne Carreira ◽

Brent S. O’Carrigan ◽

...

Keyword(s):

Phase I ◽

Cancer Patients ◽

Advanced Cancer ◽

Phase I Trial ◽

Parp Inhibitor ◽

Noninvasive Monitoring ◽

Advanced Cancer Patients ◽

Akt Inhibitor ◽

Cancer Mutations

Get full-text (via PubEx)